Corvus to share soquelitinib trial data for skin condition

BURLINGAME, Calif. - Corvus Pharmaceuticals, Inc. (NASDAQ: NASDAQ:CRVS), a clinical-stage biopharmaceutical company with a market...
1 hour ago
from: Investing.com

Corvus Pharma, NASDAQ:CRVS

More about this

- Corvus Pharmaceuticals to Announce Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis on December 18, 2024
Company to host conference call and webcast at 8:00 a.m. ET / 5:00 a.m. PT on Wednesday, December 18, 2024BURLINGAME, Calif., Dec.
from: Yahoo Finance